Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Atara Biotherapeutics (ATRA) EBITDA Margin (2022 - 2025)

Historic EBITDA Margin for Atara Biotherapeutics (ATRA) over the last 4 years, with Q3 2025 value amounting to 124.56%.

  • Atara Biotherapeutics' EBITDA Margin fell 701300.0% to 124.56% in Q3 2025 from the same period last year, while for Sep 2025 it was 15.39%, marking a year-over-year increase of 1473800.0%. This contributed to the annual value of 66.07% for FY2024, which is 31330800.0% up from last year.
  • According to the latest figures from Q3 2025, Atara Biotherapeutics' EBITDA Margin is 124.56%, which was down 701300.0% from 13.58% recorded in Q2 2025.
  • Atara Biotherapeutics' EBITDA Margin's 5-year high stood at 38.72% during Q1 2025, with a 5-year trough of 33339.37% in Q4 2022.
  • In the last 4 years, Atara Biotherapeutics' EBITDA Margin had a median value of 124.56% in 2025 and averaged 3657.44%.
  • The largest annual percentage gain for Atara Biotherapeutics' EBITDA Margin in the last 5 years was 319263100bps (2023), contrasted with its biggest fall of -74329300bps (2023).
  • Quarter analysis of 4 years shows Atara Biotherapeutics' EBITDA Margin stood at 33339.37% in 2022, then skyrocketed by 96bps to 1413.05% in 2023, then skyrocketed by 97bps to 38.8% in 2024, then crashed by -221bps to 124.56% in 2025.
  • Its EBITDA Margin stands at 124.56% for Q3 2025, versus 13.58% for Q2 2025 and 38.72% for Q1 2025.